+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-01-29Number of Pages: 100

Inhalation and Nasal Spray Generic Drugs Market:(By Drug Class: Corticosteroids, Bronchodilators, Antihistamines, Combinations, and Decongestant Sprays; By Application: Asthma, COPD, Allergic Rhinitis, and Others) Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

This report on the inhalation and nasal spray generic drugs market studies the current and future prospects of the global market. Growing incidences of respiratory diseases such as asthma and COPD, increasing geriatric population, and increasing number of generic manufacturers is expected to accentuate the growth of inhalation and nasal spray generic drugs market globally. The inhalation and nasal spray generic drugs market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments and sub-segments of the market. It also provides information and data analysis of the global inhalation and nasal spray generic drugs market with respect to market segments based on drug class, medical indication and their geographic analysis. 

Based on drug class, the inhalation and nasal spray generic drugs market has been segmented into five major categories: corticosteroids, bronchodilators, antihistamines, combinations, and decongestant sprays. The market segments have been extensively analyzed based on usefulness, efficacy, revenue, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment has been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year. 

Geographically, the global inhalation and nasal spray generic drugs market has been categorized into six major regions: North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World. The market size and forecast for each of these regions has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions. A detailed qualitative analysis of factors responsible for driving and restraining the growth of the market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis by drug class and geography, as well as market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global inhalation and nasal spray generic drugs market. 

Current and future trends has also been provided for new entrants as well as existing market players to assist them in taking strategic initiatives to establish a strong presence in the market. The report also profiles major players in the inhalation and nasal spray generic drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Allergan plc, Mylan N.V., Ranbaxy Laboraotries Ltd., Roxane Laboratories, Inc., Beximco Pharmaceuticals Ltd., Cipla Ltd., and Nephron Pharmaceuticals Corporation.

The global inhalation and nasal spray generic drugs market is segmented as given below:

Global Inhalation and Nasal Spray Generic Drugs Market, by Drug Class, 2013-2023 (US$ Mn)

  • Corticosteroids
    • Fluticasone
    • Budesonide
    • Beclomethasone
    • Flunisolide
    • Others (mometasone, ciclesonide etc.)
  • Bronchodilators
    • Albuterol
    • Epinephrine
    • Others
  • Antihistamines
  • Combinations
    • Salmeterol/Fluticasone
    • Formoterol/Budesonide
    • Azelastine/Benzalkonium Chloride
    • Others
  • Decongestant Sprays
    • Phenylephrine hydrochloride
    • Oxymetazoline hydrochloride

Global Inhalation and Nasal Spray Generic Drugs Market, by Drug Class, 2013-2023 (US$ Mn)

  • Asthma
  • COPD
  • Allergic Rhinitis
  • Other Respiratory Disorders

Global Inhalation and Nasal Spray Generic Drugs Market, by Geography, 2013 – 2023 (US$ Mn)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and North Africa
    • Saudi Arabia
    • Egypt
    • United Arab Emirates
    • Rest of MENA
  • Rest of the World (RoW)


1. Preface
    1.1. Report Description
    1.2. Market Segmentation
    1.3. Research Methodology

2. Executive Summary
    2.1. Global Inhalation and Nasal Spray Generic Drugs Market Revenue, 2013–2023 (US$ Mn)
    2.2. Global Inhalation and Nasal Spray Generic Drugs Market Revenue, by Drug Class, 2014 (US$ Mn)
    2.3. Global Inhalation and Nasal Spray Generic Drugs Market Revenue, by Medical Indication, 2014 (US$ Mn)
    2.4. Global Market Share by Geography, 2014 and 2023 (Value %)
    2.5. Inhalation and Nasal Spray Generic Drugs Market Snapshot

3. Global Inhalation and Nasal Spray Generic Drugs Market – Industry Analysis
    3.1. Introduction
    3.2. Drivers
          3.2.1. Rise in incidence of asthma, COPD, and other respiratory diseases to provide an impetus for growth
          3.2.2. Low cost involved with generic prescription drugs
    3.3. Restraints
          3.3.1. Stringent regulatory policies for generic drugs in developing countries
    3.1. Opportunities
          3.1.1. Patent expiry of blockbuster drugs would provide new opportunities for generic drug manufacturers
    3.2. Market Attractiveness Analysis – Inhalation and Nasal Spray Generic Drugs Market, By Drug Class
    3.3. Market Attractiveness Analysis – Inhalation and Nasal Spray Generic Drugs Market, By Geography
    3.4. Company Market Share – Inhalation and Nasal Spray Generic Drugs Market (2014) (%) 
    3.5. Patient Pool Analysis, by Medical Indication
    3.6. Regulatory Framework for U.S.
    3.7. Regulatory Framework for Europe

4. Market Segmentation – By Drug Class
    4.1. Introduction
    4.2. Global Corticosteroids Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.2.1. Global Fluticasone Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.2.2. Global Budesonide Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.2.3. Global Beclomethasone Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.2.4. Global Flunisolide Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.2.5. Global Other Corticosteroids Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
    4.3. Global Bronchodilators Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.3.1. Global Albuterol Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.3.2. Global Epinephrine Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.3.3. Global Other Bronchodilators Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
    4.4. Global Antihistamines Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
    4.5. Global Combinations Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.5.1. Global Salmeterol/Fluticasone Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.5.2. Global Formoterol/Budesonide Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.5.3. Global Azelastine/Benzalkonium Chloride Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.5.4. Global Other Combination Drugs Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
    4.6. Global Decongestant Sprays Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.6.1. Global Phenylephrine Hydrochloride Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)
          4.6.2. Global Oxymetazoline Hydrochloride Market for Inhalation and Nasal Spray Generic Drugs, 2013–2023 (US$ Mn)

5. Market Segmentation – By Medical Indication
    5.1. Introduction
    5.2. Global Inhalation and Nasal Spray Generic Drugs Market for Asthma, 2013–2023 (US$ Mn)
    5.3. Global Inhalation and Nasal Spray Generic Drugs Market for COPD, 2013–2023 (US$ Mn)
    5.4. Global Inhalation and Nasal Spray Generic Drugs Market for Allergic Rhinitis, 2013–2023 (US$ Mn)
    5.5. Global Inhalation and Nasal Spray Generic Drugs Market for Other Respiratory Disorders, 2013–2023 (US$ Mn)

6. Inhalation and Nasal Spray Generic Drugs Market - Regional Analysis
    6.1. Global Inhalation and Nasal Spray Generic Drugs Market: Regional Overview
    6.2. North America Inhalation and Nasal Spray Generic Drugs Market Overview
    6.3. Europe Inhalation and Nasal Spray Generic Drugs Market Overview
    6.4. Asia Pacific Inhalation and Nasal Spray Generic Drugs Market Overview
    6.5. Latin America Inhalation and Nasal Spray Generic Drugs Market Overview
    6.6. Middle East and North Africa Inhalation and Nasal Spray Generic Drugs Market Overview
    6.7. RoW Inhalation and Nasal Spray Generic Drugs Market Overview

7. Historical Snapshot and Current Trends

8. Company Profiles.
    8.1. Allergan plc
    8.2. Beximco Pharmaceuticals
    8.3. Cipla Ltd. 
    8.4. Mylan N.V. 
    8.5. Nephron Pharmaceuticals Corporation
    8.6. Ranbaxy Laboratories Ltd. 
    8.7. Roxane Laboratories, Inc.
    8.8. Sandoz International GmbH (Novartis AG) 
    8.9. Teva Pharmaceutical Industries Ltd. 

Inhalation and nasal spray generic drugs are subject to regulation of countries where they are dispensed. Factors such as low cost of manufacturing, lesser drug time approval, and potential quality and performance characteristics are few of the factors driving the inhalation and nasal spray generic drugs market.

Based on drug class, the inhalation and nasal spray generic drugs market has been categorized into five segments: corticosteroids, bronchodilators, antihistamines, combinations, and decongestant sprays. The combinations segment dominated the inhalation and nasal spray generic drugs market, accounting for a share of 38.8% in 2014 due to better compliance and increased efficiency. The segment is also expected to register the fastest growth during the forecast period.

Based on application, the inhalation and nasal spray generic drugs market has been segmented into four types based on medical application: asthma, COPD, allergic rhinitis, and others (cystic fibrosis, influenza, etc.) The asthma segment held the largest market share of 55.3% in 2014. The asthma segment is projected to expand at the fastest CAGR during the forecast period. Major factors driving the asthma segment are increasing pollution and excessive use of tobacco among the population. Furthermore, various respiratory infections are instigating severe lung damages, consequently leading to asthma, thereby boosting the growth of the asthma segment during the forecast period from 2015 to 2023.

Geographically, North America dominated the inhalation and nasal spray generic drugs market in 2014, accounting for a share of 38.5% due to factors such as rising prevalence of asthma, COPD and other fatal respiratory disorders, and increasing number of government initiatives. Additionally, growing preference of the population for affordable generic drugs is another factor supporting market growth in this region. Asia Pacific is projected to be the most lucrative market for inhalation and nasal spray generic drugs and is expected to expand at the highest growth rate of 6.3% from 2015 to 2023. Factors propelling the growth of the inhalation and nasal spray generic drugs market in Asia Pacific are presence of large population base, rising disposable income among the population, and increasing health care awareness among the people pertaining to inexpensive generic drugs.

Teva Pharmaceutical Industries Ltd. dominated the inhalation and nasal spray generic drugs market in 2014 with a market share of 15.8%. Major factors attributed to its dominance are broad product portfolio and widespread market presence. Sandoz International GmbH (Novartis AG) was the second largest player offering a wide range of inhalation and nasal spray generic drugs. Other players in the inhalation and nasal spray generic drugs market include Allergan plc, Mylan N.V., Nephron Pharmaceuticals Corporation, Ranbaxy Laboratories Ltd., Cipla Ltd., Roxane Laboratories, Inc., and Beximco Pharmaceuticals.

 

inhalation-nasal-spray-generic-drugs

 


A complete brochure for this research is available for download.

Interact with our pool of experienced analysts for any report related queries